Navigation Links
New Test Developed to Identify LQTS syndrome

Researchers at the Mayo Clinic have discovered the epinephrine QT stress test that can predict the long QT syndrome with an accuracy of about 75%. //

The Long QT syndrome is a rare yet almost fatal, heart rhythm disorder occurring right from birth and affecting about one in every 3000 people in the United States. Its name comes from the elongated Qt interval seen in the electrocardiogram (ECG ) of such people with the disease.

If untreated, 50% of the people with symptoms of LQTS will die within 10 years of the first diagnosis of the disease.

However type 1 LQTS, a common subtype of the LQTS syndrome may go unrecognized because the patient’s resting ECG could be normal. In the epinephrine QT stress test, a patient is medicated to stimulate the heart in such a way that it mimics exercise revealing concealed type 1 long QT syndrome with an accuracy of about 75%.

This in turn can be confirmed by a blood test for LQTS genetic testing.

147 individuals, ages 8-59, who been referred to Mayo Clinic’s Long QT Syndrome Clinic during the period between 1999 and 2002 had an epinephrine QT stress test. A paradoxical lengthening of the QT interval was observed in 96%of these patients during infusion of the epinephrine.

These results could help physicians to recognize, evaluate and diagnose LQTS.

Although the treatment for LQTS patients can vary the options include medication or the implantation of a cardioverter defibrillator.


'"/>




Page: 1

Related medicine news :

1. Scientists Developed Map For Brain Molecular Communities
2. Scientists Developed Cheap Way To Assess Sleep
3. Diabetic Friendly Egg Developed In India
4. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
5. Cervical Cancer Vaccine To Be Developed In India
6. Anti-Microbial Coating For Use Over Biomedical Devices Developed
7. Cure for Osteoarthritis To Be Developed
8. Mice With Human Thought Processes Could Be Developed In The Future
9. Viagra Pill For Women To Be Developed
10. Male Contraceptive Pill Being Developed By Berlin Pharmaceutical
11. New Fertility Predictor Test Developed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... Aliso Viejo, California (PRWEB) , ... December 04, ... ... self-animating lower third presets that have new attractive animation styles with unique displacement ... Pro3rd Displace features 30 pre-animated lower third designs. Choose from a variety of ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: